Thrombotic complications associated with thalidomide in multiple myeloma: an old problem with new questions and quandaries in decision-making

• References

• 1 Barlogie B, Jagannath S, Desikan KR. et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 1999; 93: 55-65.
• 2 Zangari M, Anaisse E, Barlogie B. et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood 2001; 98: 1614-5.
• 3 Osman K, Comenzo R, Rajkumar V. Deep venous thrombosis and thalidomide therapy for multiple myeloma. N Engl J Med 2001; 344: 1951-2.
• 4 Camba L, Peccatori J, Pescarollo A. et al. Thalidomide and thrombosis in patients with multiple myeloma. Haematologica 2001; 86: 1108-9.
• 5 Cavo M, Zamagni E, Cellini C. et al. Deep-vein thrombosis in patients with multiple myeloma receiving first-line fhalidomide-dexa-methasone therapy. Blood 2002; 100: 2272.
• 6 Urbauer E, Kaufmann H, Nosslinger T. et al. Thromboembolic events during treatment with thalidomide. Blood 2002; 99: 4247-28.
• 7 Rajkumar SV, Hayman S, Gertz MA. et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncology 2002; 20: 4319-23.
• 8 Anagnostopoulos A, Weber D, Rankin K. et al. Thalidomide and dexamethasone for resistant multiple myeloma. Br J Haematol 2003; 121: 768-71.
• 9 Lee CK, Barlogie B, Munshi N. et al. DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma. J Clin Oncology 2003; 21: 2732-9.
• 10 Zangari M, Saghafifar F, Anaisse E. et al. Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complication. Blood Coagul Fibrinolysis 2002; 13: 187-92.
• 11 Minnema MC, Fijnheer R, De Groot PG. et al. Extremely high levels of von Willebrand factor antigen and of procoagulant factor VIII found in multiple myeloma patients are associated with activity status but not with thalidomide treatment. J Thromb Haemost 2003; 01: 445-9.
• 12 Santos AB, Llamas P, Roman A. et al. Evaluation of thrombophylic states in myeloma patients receiving thalidomide: a reasonable doubt. Br J Haematol 2003; 122: 159-67.
• 13 Barlogie B, Desikan R, Eddlemon P. et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood 2001; 98: 492-4.
• 14 Rajkumar SV, Gertz MA, Lacy MQ. et al. Thalidomide as initial therapy for early-stage myeloma. Leukemia 2003; 17: 775-9.
• 15 Flageul B, Wallach D, Cavelier-Balloy B. et al. Thalidomide and thrombosis. Ann Dermatol Venereol 2000; 127: 171-4.
• 16 Otterson GA, Monahan BP, Harold N. et al. Clinical significance of the FV:Q506 mutation in unselected oncology patients. Am J Med 1996; 101: 406-12.
• 17 Haemostasis and Thrombosis Task Force, British Committee for Standards in Haematology. Investigation and management of heritable thrombophilia. Br J Haematol 2001; 114: 512-28.
• 18 Kraaijenhagen RA, in’t Anker PS, Koopman MM. et al. High plasma concentration of factor VIIIc is a major risk for venous thromboembolism. Thromb Haemost 2000; 83: 5-9.
• 19 Tso E, Baz R, Marchant K. et al. Aspirin (ASA) prophylaxis during treatment of multiple myeloma using liposomal doxorubicin, vincristine, decreased-frequency dexametha-sone and thalidomide decreases post-treatment thrombosis. ASCO 2003; 2349a.